S&P 500   3,327.62 (-0.06%)
DOW   29,319.54 (-0.10%)
QQQ   223.62 (+0.11%)
AAPL   318.43 (-0.09%)
FB   221.02 (-0.50%)
MSFT   167.71 (+0.37%)
GOOGL   1,477.83 (-0.11%)
AMZN   1,872.73 (+0.43%)
CGC   24.72 (-0.68%)
NVDA   248.74 (-0.22%)
BABA   221.81 (-2.47%)
MU   58.39 (+1.27%)
GE   11.67 (-1.27%)
TSLA   544.20 (+6.60%)
AMD   51.46 (+1.04%)
T   38.44 (+0.16%)
ACB   2.06 (-3.29%)
F   9.13 (-0.44%)
NFLX   337.62 (-0.60%)
BAC   34.43 (-0.84%)
GILD   62.69 (-0.46%)
DIS   143.65 (-0.48%)
S&P 500   3,327.62 (-0.06%)
DOW   29,319.54 (-0.10%)
QQQ   223.62 (+0.11%)
AAPL   318.43 (-0.09%)
FB   221.02 (-0.50%)
MSFT   167.71 (+0.37%)
GOOGL   1,477.83 (-0.11%)
AMZN   1,872.73 (+0.43%)
CGC   24.72 (-0.68%)
NVDA   248.74 (-0.22%)
BABA   221.81 (-2.47%)
MU   58.39 (+1.27%)
GE   11.67 (-1.27%)
TSLA   544.20 (+6.60%)
AMD   51.46 (+1.04%)
T   38.44 (+0.16%)
ACB   2.06 (-3.29%)
F   9.13 (-0.44%)
NFLX   337.62 (-0.60%)
BAC   34.43 (-0.84%)
GILD   62.69 (-0.46%)
DIS   143.65 (-0.48%)
S&P 500   3,327.62 (-0.06%)
DOW   29,319.54 (-0.10%)
QQQ   223.62 (+0.11%)
AAPL   318.43 (-0.09%)
FB   221.02 (-0.50%)
MSFT   167.71 (+0.37%)
GOOGL   1,477.83 (-0.11%)
AMZN   1,872.73 (+0.43%)
CGC   24.72 (-0.68%)
NVDA   248.74 (-0.22%)
BABA   221.81 (-2.47%)
MU   58.39 (+1.27%)
GE   11.67 (-1.27%)
TSLA   544.20 (+6.60%)
AMD   51.46 (+1.04%)
T   38.44 (+0.16%)
ACB   2.06 (-3.29%)
F   9.13 (-0.44%)
NFLX   337.62 (-0.60%)
BAC   34.43 (-0.84%)
GILD   62.69 (-0.46%)
DIS   143.65 (-0.48%)
S&P 500   3,327.62 (-0.06%)
DOW   29,319.54 (-0.10%)
QQQ   223.62 (+0.11%)
AAPL   318.43 (-0.09%)
FB   221.02 (-0.50%)
MSFT   167.71 (+0.37%)
GOOGL   1,477.83 (-0.11%)
AMZN   1,872.73 (+0.43%)
CGC   24.72 (-0.68%)
NVDA   248.74 (-0.22%)
BABA   221.81 (-2.47%)
MU   58.39 (+1.27%)
GE   11.67 (-1.27%)
TSLA   544.20 (+6.60%)
AMD   51.46 (+1.04%)
T   38.44 (+0.16%)
ACB   2.06 (-3.29%)
F   9.13 (-0.44%)
NFLX   337.62 (-0.60%)
BAC   34.43 (-0.84%)
GILD   62.69 (-0.46%)
DIS   143.65 (-0.48%)
Log in
(Ad)
2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

NASDAQ:NXTC - NextCure Stock Price, Forecast & News

$49.84
-0.28 (-0.56 %)
(As of 01/21/2020 11:49 AM ET)
Today's Range
$49.28
Now: $49.84
$51.28
50-Day Range
$44.23
MA: $54.46
$66.06
52-Week Range
$13.86
Now: $49.84
$109.00
Volume1,033 shs
Average Volume254,813 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-22,800,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.13 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) announced its earnings results on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The firm had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

6 Wall Street analysts have issued 1-year target prices for NextCure's stock. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's stock price to reach $66.17 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

Press coverage about NXTC stock has been trending very positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for NextCure.

Are investors shorting NextCure?

NextCure saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, an increase of 120.1% from the December 15th total of 472,500 shares. Based on an average daily volume of 558,700 shares, the days-to-cover ratio is currently 1.9 days. Currently, 9.2% of the shares of the stock are short sold. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Alibaba Group (BABA), NVIDIA (NVDA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Home Depot (HD), Mcdonald's (MCD) and Procter & Gamble (PG).

When did NextCure IPO?

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

Who are NextCure's major shareholders?

NextCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.06%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which major investors are buying NextCure stock?

NXTC stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $49.84.

How big of a company is NextCure?

NextCure has a market capitalization of $1.13 billion. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  61
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel